35 results about "Mixed irritable bowel syndrome" patented technology

The Chinese medicine composition for treating intestinal irritable syndrome is prepared with gallnut, nutmeg, red ginseng, deglued antler powder, dark plum and myrobalan fruit as material and through the technological process including water extraction, extracting volatile oil, inclusion with cyclodextrin, grinding into fine powder and other steps. The pharmacological experiments show that the medicine of the present invention can inhibit the motion of small intestine, resist the sthenic motion of small intestine caused by Neostigmine, resist diarrhea caused by rhubarb, promote the absorption of water inside intestine caused by mannitol, etc. and has relatively high anti-diarrhea effect and high safety.

The invention discloses oral administration of a traditional Chinese medicine composition for treating irritable bowel syndrome, belonging to traditional Chinese medicine art. The oral traditional Chinese medicine composition for treating irritable bowel syndrome has drug materials as active ingredients with the following weight ratios (wt.%): 15 radix codonopsitis, 18 radix paeoniae alba, 20 Chinese yam rhizome, 25 coat of hyacinth bean, 15 poria, 10 shizandra berry, 10 radix bupleuri, 10 cabline patchouli, 10 medicated leaven, 15 Chinese atractylodes, 9 dried orange peel, 10 radix sileris, and 10 toasted rhizoma atractylodis alba. The composition is taken by herbal decoction. After combining the above drugs in the invention, the composition has synergistic reactions of strengthening spleen and warming zhong, removing dampness and guiding stagnancy, and harmonizing intestine-stomach. The oral traditional Chinese medicine composition has remarkable effect for treating the irritable bowel syndrome with reliable curative effect and no toxic and side effect.

The invention discloses a Chinese herb extract composition for treating functional gastrointestinal disorder or irritable bowel syndrome, a preparation method and application of the composition to preparation of a medicine. The Chinese herb extract composition comprises the following Chinese medicinal herb extracts in parts by weight: 13-29 parts of langehead atractylodes rhizome extract I, 18-57 parts of langehead atractylodes rhizome extract II, 13-53 parts of radix paeoniae alba extract, 6-32 parts of pericarpium citri reticulatae extract and 2-27 parts of divaricate saposhnikovia root extract, wherein the langehead atractylodes rhizome extract I is an extract of a distillation method or supercritical extraction method; the langehead atractylodes rhizome extract II is a water extract; the radix paeoniae alba extract is an alcohol extract; the pericarpium citri reticulatae extract is an alcohol extract; the divaricate saposhnikovia root extract is an aqueous extract or supercritical extract. According to the Chinese herb extract composition, the conventional view that co-decocting or total extracting of a Chinese herbal compound is superior to respective extracting of each Chinese medicinal herb is overcome, the pharmacological effect is remarkably improved through optimized combined treatment of each Chinese medicinal herb extract, and the quality control of the composition is facilitated. The Chinese herb extract composition for treating functional gastrointestinal disorder or irritable bowel syndrome, disclosed by the invention, has an unexpected effect.

An application of the galangin in preparing the medicines for treating irritable bowel syndrome (IBS) is disclosed. The preparing process for extracting galangin features use of alcohol extracting-water deposition method to obtain coarse extract and use of macroreticular resin technique and glucosan gel technique to separate and purify it.

The invention discloses a pharmaceutical composition for preventing or treating an irritable bowel syndrome. A menthol or paeoniflorin extract, or menthol and paeoniflorin is used as active components, and the medicine in different preparation types can be prepared by adding pharmaceutical acceptable auxiliary materials. The pharmaceutical composition has the definite effective components, small dosage and good safety. Pharmacodynamic tests prove that the pharmaceutical composition has a spasmolysis function, an anti-inflammatory function and an analgetic function definitely, and the pharmaceutical composition has good curative effects for the diarrhetic irritable bowel syndrome.

The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder.

A method for prophylactically treating irritable bowel syndrome in a mammal through the administration of a zinc carnosine composition like zinc carnosine is provided, although other forms of zinc carnosine or other components exhibiting zinc carnosine activity like other metal carnosine complexes may be used. The effective amount of composition to be used will depend upon such factors as the age and weight of the mammal, and whether treatment of existing IBS symptoms, or prevention of the onset of IBS symptoms is desired. A complex comprising such a zinc carnosine composition for prophylactically treating IBS in a mammal is also provided.

The invention provides traditional Chinese medicinal enteric-coated tablets for treating proctitis, colitis and irritable bowel syndrome, as well as a preparation method and application thereof. Active components for preparing the traditional Chinese medicinal enteric-coated tablets comprise the following traditional Chinese medicinal raw materials in parts by weight: 200-800 parts of smoked plum, 50-400 parts of golden thread, 50-400 parts of dried ginger, 50-400 parts of costustoot, 50-300 parts of pericarpium papaveris, and 50-300 parts of rhizoma corydalis. Clinical researches on ulcerative colitis prove that, the traditional Chinese medicinal enteric-coated tablets have a cure rate of 59.1 percent in a treatment group, and a total effective rate of 98.1 percent. Clinical researches on irritable bowel syndrome prove that traditional Chinese medicinal enteric-coated tablets have a complete remission rate of 67.8 percent in the treatment group, and a total effective rate of 95.2 percent. In clinical researches on proctitis, the traditional Chinese medicinal enteric-coated tablets are used for treating 36 cases, wherein 32 cases are cured, 3 cases are improved, 1 case is invalid, and the total effective rate is 88.8 percent. The researches prove that the enteric-coated tablets have remarkable advantages and improvement in treatment after the preparation and dose forms are improved, and are advantageous to clinical application. The traditional Chinese medicinal enteric-coated tablets are easily available in raw materials, simple in method and pollution free, is suitable for industrial production, and has higher application value.

The invention discloses application of mir-146a-5p to treating visceral hypersensitivity of irritable bowel syndrome. The mir-146a-5p is low in expression in peripheral serum of patients with visceralhypersensitivity of irritable bowel syndrome and intestinal mucosa of disease model mice with irritable bowel syndrome; meanwhile, after the disease model mice of irritable bowel syndrome receive intraperitoneal injection of hsa-mir-146a-5p agomir to achieve high expression of mir-146a-5p, the visceral sensitivity of the disease model mice is significantly reduced, so that the effectiveness of mir-146a-5p on reducing visceral hypersensitivity of the irritable bowel syndrome can be proved, and an effective way for treating visceral hypersensitivity of irritable bowel syndrome can be provided.

The present invention is directed to the prevention, reversal and medical treatment of lower urinary tract dysfunction including bladder instability and other related diseases as described below including urinary flow problems, urgency and incontinence as a result of prostate hyperplasia (BPH) and to the prevention, reversal and medical treatment of irritable bowl syndrome (IBS) with special focus on the diarrhea-predominant and mixed diarrhea-constipation type IBS, both in human beings and animals.

The invention discloses a medicine for treating irritable bowel syndrome in the field of traditional Chinese medicines. The content of elecampane total lactone is more than 70 percent, and the content of alantolactone and isoalantolactone accounts for over 90 percent of the total lactone. The used elecampane total lactone has the characteristics of well improving gastrointestinal motility and relieving pain and is exact in curative effect on gastrointestinal functional disorder. According to pharmacological testing and screening, the elecampane total lactone is determined to have good curative effects on diarrhea-type and constipation-type irritable bowel syndrome (IBS), and the IBS symptoms can be obviously relieved.

The invention discloses a paeoniflorin composition for treating gastrointestinal dysfunction or irritable bowel syndrome and application thereof. The paeoniflorin composition for treating gastrointestinal dysfunction or irritable bowel syndrome is composed of paeoniflorin and a component A. The component A comprises one or a combination of more than one of naringin, hesperidin, neohesperidin, isoliquiritin, liquiritin and glycyrrhizic acid. By selectively using the natural composition, the paeoniflorin composition has synergistic regulation and multi-target correction effects on a 5-HT signalchannel. The fact that the optimized combination of natural components has more excellent effect than original single component or a Chinese herbal compound extract is put forward in the invention. Onthis basis, ratio of the composition is further optimized, and the best effect is achieved.

A method for treatment of a patient suffering from irritable bowel syndrome with diarrhea or mixed irritable bowel syndrome, which comprises administering to the patient a therapeutically effective amount of ramosetron or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of polycarbophil or a pharmaceutically acceptable salt thereof.

The invention discloses a paeoniflorin/synephrine composition for treating gastrointestinal dysfunction or irritable bowel syndrome and application thereof. The paeoniflorin/synephrine composition fortreating gastrointestinal dysfunction or irritable bowel syndrome contains at least two active ingredients of paeoniflorin and synephrine. The invention selectively adopts a combination of natural components, wherein the combination has synergistic regulation and multi-target rectification effect on 5HT signaling pathway, and puts forward the fact that the optimum composition of natural components has better effect than original single ingredient or compounded traditional Chinese medicine extracts. On the basis, the combination ratio is further optimized to achieve the best results.

The invention provides a drug for treating an irritable bowel syndrome by cooperating with a gastric motivity therapeutic instrument. The drug is prepared from 3 parts of litchi seeds, 5 parts of dried hyacinth beans, 2.5 parts of dried ginger, 8 parts of glycerin, 2 parts of fumed silica and 1.5 parts of micro carbonized corn flour. A preparation method of the drug comprises the steps that the litchi seeds are crushed and then mixed with the dried hyacinth beans and the dried ginger, and then all the materials are ground into powder A; the micro carbonized corn flour is mixed with glycerin and fumed silica, grinding is conducted till the granule size distribution of the micro carbonized corn flour ranges from 60 micrometers to120 micrometers, and a material B is obtained; the powder A is added to the material B, the materials are stirred and mixed to be uniform and subjected to cold storage for 10 min in an environment of -15 DEG C, the materials are taken out, the temperature is naturally raised to 5 DEG C or above, and the drug is obtained. According to the drug for treating the irritable bowel syndrome by cooperating with the gastric motivity therapeutic instrument, the drug and the gastric motivity therapeutic instrument are mutually synergistic, under the current irritation of the gastric motivity therapeutic instrument, drug absorption is rapid, the utilization ratio of the drug is high, and the drug efficacy is obvious; under the adjuvant therapy of the drug, the therapeutic effect of the gastric motivity therapeutic instrument on the irritable bowel syndrome is more obvious, the effect is rapid to achieve, and the treatment cycle is shortened.

The invention discloses a compound for treating irritable bowel syndrome through transplanting of prebiotics and fecal bacteria. The preparation method comprises the following steps: (1) preparing standard fecal bacterium liquid; (2) preparing compound prebiotic liquid; and (3) preparing prebiotic-fecal bacterium liquid composite liquid. Clinical research proves that the effect for treating the irritable bowel syndrome by the prebiotic-fecal bacterium liquid composite liquid is more excellent than that of single use of prebiotic or fecal bacteri transplanting.

The invention relates to a traditional Chinese medicine for treating diarrhea-predominant irritable bowel syndromes, belonging to the technical field of medicines. The traditional Chinese medicine is prepared from the following raw materials: 8-12g of radix aconiti praeparata, 8-12g of cinnamon, 8-12g of rhizoma zingiberis, 12-18g of codonopsis pilosula, 12-18g of roasted rhizoma atractylodis macrocephalae, 25-35g of semen coicis, 5-7 Chinese-dates and 5-7g of honey-fried licorice root. According to the formula disclosed by the invention, the medicines have the effects of warming yang and dispelling cold and replenishing qi to invigorate the spleen, has a good effect of treating the diarrhea-predominant irritable bowel syndromes, is low in cost and does not have any toxic or side effect, the effective rate is 98 percent, and the cure rate is over 95 percent.

The invention discloses traditional Chinese medicine composition for treating intestinal stasis type IBS (irritable bowel syndrome). The composition is prepared from the following medicinal materials in parts by weight: 50-60 parts of embelia longifolia, 25-30 parts of polygonum hydropiper, 12-15 parts of herbs of nepal pennywort, 12-15 parts of green walnut peel, 25-30 parts of herbs of clinopodium, 10-15 parts of herba polygoni perfoliati, 12-15 parts of lychnis senno sieb. et zucc., 25-30 parts of shorthairy antenoron herbs, 10-15 parts of alternanthera sessilis, 25-30 parts of roots of Chinese loropetalum, 15-20 parts of roots of cherokee rose, 50-60 parts of Chinese pearleaf crabapple, 12-15 parts of sweet basil herbs, 6-9 parts of rhizomes of broadleaf common valeriana and 9-12 parts of liquorice. The traditional Chinese medicine composition is used for intestinal stasis type IBS, and is high in effective rate and reliable in curative effect; recurrence is prevented after IBS is cured.